SCHEMBL4945322

SCHEMBL4945322

COC(=O)c1ccc(CCN(NCCC(C)=O)C(C)=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 2/20 0.49
CYP4F2 P78329 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.45
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
CYP2C19 P33261 1/20 0.42
CKS1B P61024 1/20 0.42
SKP2 Q13309 1/20 0.42
HIF1A Q16665 1/20 0.42
MGLL Q99685 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5983170 0.91 CYP4A11 (0.48) CYP4A11CYP4F2LOXL2ALDH1A1HPGD
SCHEMBL4947062 0.85 CYP4A11 (0.45) CYP4A11CYP4F2LOXL2ALDH1A1HPGD
SCHEMBL4941662 0.84 CYP4A11 (0.45) CYP4A11CYP4F2LOXL2CYP1A2CYP3A4
SCHEMBL4941562 0.83 CYP4A11 (0.54) CYP4A11CYP4F2LOXL2ALDH1A1HPGD
SCHEMBL4937150 0.79 CYP4A11 (0.42) CYP4A11CYP4F2LOXL2ALDH1A1MGLL
SCHEMBL1629577 0.79 CYP4A11 (0.64) CYP4A11CYP4F2LOXL2ALDH1A1HPGD
SCHEMBL5982597 0.78 CYP4A11 (0.44) CYP4A11CYP4F2LOXL2CYP1A2CYP3A4
SCHEMBL3933575 0.76 CYP4A11 (0.70) CYP4A11CYP4F2LOXL2ALDH1A1HPGD
SCHEMBL4937870 0.76 LOXL2 (0.56) CYP4A11CYP4F2LOXL2ALDH1A1HPGD
SCHEMBL4946101 0.75 CYP4A11 (0.46) CYP4A11CYP4F2LOXL2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465755-B2 Hydrazide derivatives as prostaglandin receptors modulators LABORATOIRES SERONO SA (CH) 2008-12-16 US disclosed
US-20070185191-A1 Hydrazide derivatives as prostaglandin receptors modulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US disclosed
EP-1654219-A2 HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2006-05-10 EP disclosed
WO-2005012232-A2 HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185191-A1 Hydrazide derivatives as prostaglandin receptors modulators PTGIR, HPGDS, PGF CYP4A11 103/4885CYP4F2 386/4885LOXL2 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.